| Literature DB >> 26240279 |
Salvatore Fabbiano1, Mauricio Menacho-Márquez1, Javier Robles-Valero1, Miguel Pericacho2, Adela Matesanz-Marín3, Carmen García-Macías1, María A Sevilla2, M J Montero2, Balbino Alarcón4, José M López-Novoa2, Pilar Martín3, Xosé R Bustelo5.
Abstract
Hypertension-associated cardiorenal diseases represent one of the heaviest burdens for current health systems. In addition to hemodynamic damage, recent results have revealed that hematopoietic cells contribute to the development of these diseases by generating proinflammatory and profibrotic environments in the heart and kidney. However, the cell subtypes involved remain poorly characterized. Here we report that CD39(+) regulatory T (TREG) cells utilize an immunosuppression-independent mechanism to counteract renal and possibly cardiac damage during angiotensin II (AngII)-dependent hypertension. This mechanism relies on the direct apoptosis of tissue-resident neutrophils by the ecto-ATP diphosphohydrolase activity of CD39. In agreement with this, experimental and genetic alterations in TREG/TH cell ratios have a direct impact on tissue-resident neutrophil numbers, cardiomyocyte hypertrophy, cardiorenal fibrosis, and, to a lesser extent, arterial pressure elevation during AngII-driven hypertension. These results indicate that TREG cells constitute a first protective barrier against hypertension-driven tissue fibrosis and, in addition, suggest new therapeutic avenues to prevent hypertension-linked cardiorenal diseases.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26240279 PMCID: PMC4573708 DOI: 10.1128/MCB.00518-15
Source DB: PubMed Journal: Mol Cell Biol ISSN: 0270-7306 Impact factor: 4.272